Tests daraxonrasib against docetaxel in previously treated lung cancer with RAS mutations
Compares daraxonrasib with docetaxel in adults with previously treated RAS-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Key facts
- Where
- Bordeaux, Brest, Bron, Creteil Cedex, Grenoble Cedex 9, Lille, Lyon, Marseille, Montpellier Cedex 5, Paris, Paris Cedex 18, Rennes Cedex 9, Saint-Herblain, Saint-Herblain Cedex, Strasbourg Cedex, Toulouse, and Villejuif, FranceSee the 17 sites
- Phase
- Phase 3
Where in France
- Institut BergonieBordeaux, FranceNo longer taking part
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceNo longer taking part
- Hospices Civils de LyonBron, FranceNo longer taking part
- Centre Hospitalier Intercommunal CreteilCreteil Cedex, FranceNo longer taking part
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceNo longer taking part
- Centre Hospitalier Universitaire de LilleLille, FranceNo longer taking part
- Centre Leon BerardLyon, FranceNo longer taking part
- Centre Hospitalier Regional De MarseilleMarseille, FranceNo longer taking part
- Institut Regional Du Cancer De MontpellierMontpellier Cedex 5, FranceNo longer taking part
- Institut CurieParis, FranceNo longer taking part
- Assistance Publique Hopitaux De ParisParis Cedex 18, FranceNo longer taking part
- Centre Hospitalier Universitaire De RennesRennes Cedex 9, FranceNo longer taking part
- Centre Hospitalier Universitaire de NantesSaint-Herblain, FranceNo longer taking part
- Institut De Cancerologie De L OuestSaint-Herblain Cedex, FranceNo longer taking part
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex, FranceNo longer taking part
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceNo longer taking part
- Institut Gustave RoussyVillejuif, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT06881784EU 2024-518154-16-00
- Record updated
- 6 November 2026
- Original description
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.Read full original descriptionShow less
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Inclusion: At least 18 years old and has provided informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy; Measurable disease per RECIST v1.1; Adequate organ function (bone marrow, liver, kidney, coagulation); One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy; Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61); Able to take oral medications.
Exclusion: Prior therapy with direct RAS-targeted therapy or docetaxel; Ongoing anticancer therapy; Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function); Untreated central nervous system (CNS) metastases; Pregnant or breastfeeding.